Lombard Medical Technologies (LSE:LMT) ROCE % : -198.41% (As of Dec. 2012)

View and export this data going back to . Start your Free Trial

What is Lombard Medical Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lombard Medical Technologies's annualized ROCE % for the quarter that ended in Dec. 2012 was -198.41%.

Lombard Medical Technologies ROCE % Historical Data

The historical data trend for Lombard Medical Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lombard Medical Technologies ROCE % Chart

Lombard Medical Technologies Annual Data

Trend

Sep02

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

ROCE %

Get a 7-Day Free Trial

-209.80

-158.76

-112.47

-102.53

-99.94

Lombard Medical Technologies Semi-Annual Data
	Sep02	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12
ROCE %	Get a 7-Day Free Trial					-263.15	-141.29	-87.24	-92.43	-198.41

Lombard Medical Technologies ROCE % Calculation

Lombard Medical Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2012 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2012 )		(A: Dec. 2011 )		(A: Dec. 2012 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2012 )		(A: Dec. 2011 )		(A: Dec. 2012 )
	=	-8.244	/	( ( (15.305 - 2.962)	+	(9.241 - 5.086) )	/ 2 )
	=	-8.244	/	( (12.343	+	4.155)	/ 2 )
	=	-8.244	/	8.249
	=	-99.94 %

Lombard Medical Technologies's ROCE % of for the quarter that ended in Dec. 2012 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2012 )		(Q: Dec. 2011 )		(Q: Dec. 2012 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2012 )		(Q: Dec. 2011 )		(Q: Dec. 2012 )
	=	-8.244	/	( ( (15.305 - 2.962)	+	(9.241 - 5.086) )	/ 2 )
	=	-8.244	/	( ( 12.343	+	4.155 )	/ 2 )
	=	-8.244	/	8.249
	=	-99.94 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2012) EBIT data.

Lombard Medical Technologies (LSE:LMT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lombard Medical Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Lombard Medical Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lombard Medical Technologies (LSE:LMT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lombard Medical Technologies PLC (LSE:LMT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.lombardmedical.com

Lombard Medical Technologies PLC is engaged in the design and development of endovascular stent grafts, their manufacture, and commercialization either directly through the group's own sales force or through a network of local distributors supported by clinical specialists from Lombard Medical. The principal product, the AorfixT AAA stent graft has European CE mark approval for use in patients with high-angle-neck aneurysms of up to 90 degrees. The group has operations in United Kingdom and United States of America.